Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate
GAITHERSBURG, Md., Aug. 4 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID‑19 vaccine with and without Matrix‑M™ adjuvant in healthy adults 18-59 years of age. NVX‑CoV2373, the Company’s recombinant [...]